TY - JOUR
T1 - Forecasting the future of cardiovascular disease in the United States
T2 - A policy statement from the American Heart Association
AU - Heidenreich, Paul A.
AU - Trogdon, Justin G.
AU - Khavjou, Olga A.
AU - Butler, Javed
AU - Dracup, Kathleen
AU - Ezekowitz, Michael D.
AU - Finkelstein, Eric Andrew
AU - Hong, Yuling
AU - Johnston, S. Claiborne
AU - Khera, Amit
AU - Lloyd-Jones, Donald M.
AU - Nelson, Sue A.
AU - Nichol, Graham
AU - Orenstein, Diane
AU - Wilson, Peter W F
AU - Woo, Y. Joseph
PY - 2011/3/1
Y1 - 2011/3/1
N2 - Background- Cardiovascular disease (CVD) is the leading cause of death in the United States and is responsible for 17% of national health expenditures. As the population ages, these costs are expected to increase substantially. Methods and Results- To prepare for future cardiovascular care needs, the American Heart Association developed methodology to project future costs of care for hypertension, coronary heart disease, heart failure, stroke, and all other CVD from 2010 to 2030. This methodology avoided double counting of costs for patients with multiple cardiovascular conditions. By 2030, 40.5% of the US population is projected to have some form of CVD. Between 2010 and 2030, real (2008$) total direct medical costs of CVD are projected to triple, from $273 billion to $818 billion. Real indirect costs (due to lost productivity) for all CVD are estimated to increase from $172 billion in 2010 to $276 billion in 2030, an increase of 61%. Conclusions- These findings indicate CVD prevalence and costs are projected to increase substantially. Effective prevention strategies are needed if we are to limit the growing burden of CVD.
AB - Background- Cardiovascular disease (CVD) is the leading cause of death in the United States and is responsible for 17% of national health expenditures. As the population ages, these costs are expected to increase substantially. Methods and Results- To prepare for future cardiovascular care needs, the American Heart Association developed methodology to project future costs of care for hypertension, coronary heart disease, heart failure, stroke, and all other CVD from 2010 to 2030. This methodology avoided double counting of costs for patients with multiple cardiovascular conditions. By 2030, 40.5% of the US population is projected to have some form of CVD. Between 2010 and 2030, real (2008$) total direct medical costs of CVD are projected to triple, from $273 billion to $818 billion. Real indirect costs (due to lost productivity) for all CVD are estimated to increase from $172 billion in 2010 to $276 billion in 2030, an increase of 61%. Conclusions- These findings indicate CVD prevalence and costs are projected to increase substantially. Effective prevention strategies are needed if we are to limit the growing burden of CVD.
KW - AHA Scientific Statements
KW - US costs
KW - cardiovascular diseases
KW - cost analysis
KW - forecasting
UR - http://www.scopus.com/inward/record.url?scp=79952444246&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952444246&partnerID=8YFLogxK
U2 - 10.1161/CIR.0b013e31820a55f5
DO - 10.1161/CIR.0b013e31820a55f5
M3 - Article
C2 - 21262990
AN - SCOPUS:79952444246
SN - 0009-7322
VL - 123
SP - 933
EP - 944
JO - Circulation
JF - Circulation
IS - 8
ER -